FDA accepts a biologic license application for AstraZeneca immunotherapy imfinzi (durvalumab)
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Small cell lung cancer is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer casesAbout three-quarters of those with small cell lung cancer were diagnosed at the time of diagnosis, which had been widely metastasized in the lungs, or had been in other parts of the bodyRecently, AstraZeneca announced that the U.SFDA(http://accepted its immunotherapy, the durvalumab supplemental biologic license application (sBLA), and granted the application as a priority reviewAs a PD-L1 inhibitor, Imfinzi demonstrated positive therapeutic effects in a Phase 3 clinicaltrial(http://called CASPIANWhen used in combination with standard chemotherapy, it can significantly extend the patient's total survival (OS)The data showed that the patient's risk of death was reduced by 27%, with a median total survival of 13.0 monthsIn contrast, the control group, which used only standard chemotherapy, had a data of 10.3 monthsAfter 18 months of treatment, 33.9% of the patients in the treatment group survivedThis figure was 24.7 per cent in the control groupThe results of the study were also published in The Lancet earlier this year
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
